Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease

Dahham Alsoud, Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
Nurulamin M. Noor, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Lea Ann Chen, Division of Gastroenterology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Vivian Abadom, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Simon H. Anderson, Department of Gastroenterology, Guy's & St Thomas' Hospital, London, UK.
Lediona Ardolli, PredictImmune Ltd, Cambridge, UK.
Jordan Axelrad, Division of Gastroenterology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Peter Bossuyt, Department of Gastroenterology, Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium.
Kenneth Croitoru, Division of Gastroenterology, University of Toronto, Mount Sinai Hospital, Toronto, Canada.
Oriana M. Damas, Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Lily Deng, Department of Medicine, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Parakkal Deepak, Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA.
Juan De Negro, Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
Shanika de Silva, Department of Gastroenterology, Dudley Group NHS Foundation Trust, Dudley, UK.
Marc Ferrante, Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
Karen Hills, Juneberry Ltd, Cambridge, UK.
Peter M. Irving, Department of Gastroenterology, Guy's & St Thomas' Hospital, London, UK.
James O. Lindsay, Department of Gastroenterology, Barts Health NHS Trust, London, UK.
Dana J. Lukin, Department of Gastroenterology and Hepatology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.
Paul A. Lyons, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Eoin F. McKinney, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Maria Oliva-Hemker, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Caterina Oneto, Vanguard Gastroenterology Clinic, New York, New York, USA.
Roohi Patel, Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Miles Parkes, Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Lieven Pouillon, Department of Gastroenterology, Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium.
João Sabino, Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
Lawrence J. Saubermann, Division of Gastroenterology and Hepatology, University of Rochester Medical Center, Rochester, New York, USA.
Jenny S. Sauk, Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Sarah Sheibani, Division of Gastrointestinal and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Kenneth G. Smith, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Keith S. Sultan, Department of Gastroenterology, North Shore University Hospital-Long Island Jewish Medical Center, Northwell Health, Manhasset, New York, USA.

Document Type

Journal Article

Publication Date

7-11-2025

Journal

United European gastroenterology journal

DOI

10.1002/ueg2.70050

Keywords

biomarker; blood tests; corticosteroids; crohn's disease; inflammatory bowel diseases; personalised management; prognosis; treatment; ulcerative colitis

Abstract

BACKGROUND AND AIMS: PredictSURE IBD is a prognostic blood test that classifies newly diagnosed, treatment-naïve Inflammatory Bowel Disease (IBD) patients into 'IBDhi' (high-risk) or 'IBDlo' (low-risk) groups (risk of future aggressive disease). We evaluated this assay in a multinational cohort and explored the effect of concomitant corticosteroids on its discrimination. METHODS: One hundred thirty-six (71 Ulcerative colitis [UC], 65 Crohn's Disease [CD]) and 41 (15 UC, 26 CD) patients with active IBD were 'unexposed' and 'exposed', respectively, to corticosteroids at baseline blood sampling. The number of treatment escalations, time to first escalation, and need for repeated escalations were compared between the biomarker subgroups. Another 20 patients (13 UC, 7 CD) were longitudinally sampled over 6 weeks after commencing corticosteroids. RESULTS: In corticosteroids-naïve UC and CD patients, all bowel surgeries (n = 6) and multiple therapy escalations (n = 10) occurred in IBDhi patients. IBDhi UC patients required significantly more treatment escalations, had a shorter time to first escalation, and a greater need for multiple escalations than IBDlo patients. No statistically significant differences were observed among CD patients. In corticosteroid-exposed patients, 66.6% of 'misclassifications' were IBDlo patients who required escalations. Among corticosteroid-treated patients with longitudinal sampling, 81.3% of those classified as IBDhi before steroids switched to IBDlo during therapy. CONCLUSIONS: No significant differences in treatment escalations were observed between biomarker-defined subgroups in CD. However, IBDhi UC patients required significantly earlier and more frequent therapy escalations, highlighting the need to further investigate PredictSURE IBD in UC. Notably, the discrimination ability of the biomarker was unreliable in patients receiving corticosteroid therapy.

Department

Medicine

Link to Full Text

Share

COinS